TT-00434 / TransThera Biosci - LARVOL DELTA

First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors (ESMO Asia 2023) - P1 | "The preliminary antitumor activity was observed in pt with FGFR2 altered cholangiocarcinoma. Further evaluation of the efficacy and safety of TT-00434 in solid tumors with FGFR1-3 alterations is encouraged."

Clinical • Metastases • P1 data • Biliary Cancer • Bladder Cancer • Cholangiocarcinoma • Endometrial Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • FGFR • FGFR2

Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=11 | Completed | Sponsor: TransThera Sciences (Nanjing), Inc. | Recruiting ➔ Completed | N=20 ➔ 11 | Trial completion date: Dec 2022 ➔ Oct 2023 | Trial primary completion date: Aug 2022 ➔ Oct 2023

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: TransThera Sciences (Nanjing), Inc.; Trial completion date: Aug 2023 ➔ Dec 2022; Trial primary completion date: Apr 2023 ➔ Aug 2022

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: TransThera Biosciences Co., Ltd; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Oncology • Solid Tumor

Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=20; Not yet recruiting; Sponsor: TransThera Biosciences Co., Ltd

New P1 trial • Oncology • Solid Tumor